Search Results

Avirmax Biopharma Inc., will make three scientific presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle between May 5th and 9th, 2024.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad’s breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test.

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that RareCyte Inc., a precision biology company based in Seattle, Washington, is live on SOPHiA GENETICS.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the addition of a new Universal Plus Panel to its Foresight® Carrier Screen.

With pediatric inflammatory bowel disease diagnoses on the rise globally, a clinical trial in Seattle aims to transform treatment approaches through deep molecular profiling.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at the virtual TD Cowen Genetic Medicines & RNA Summit on Thursday, June 20, 2024.

3X4 Genetics, leader in the field of genetics-based health, announced a partnership with The Metabolic Terrain Institute of Health to serve as the innovative nonprofit’s genetics provider.

Regeneron, Akouos and Mass Eye and Ear are testing therapies that can reverse genetic protein deficiency to restore hearing, with promising early results.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting.

Seattle Children’s Research Institute, the research division of Seattle Children’s Hospital and renowned global leader in pediatric research, and Genezen, a leading gene and cell therapy contract development and manufacturing organization, have unveiled a strategic manufacturing partnership for Seattle Children’s Research Institute’s X-linked agammaglobulinemia program.